The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) study.
Jeff H. Geschwind
Consultant or Advisory Role - Bayer; Biocompatibles; BioSphere Medical; Guerbet
Research Funding - Bayer; Biocompatibles; BioSphere Medical; ContextVision; Genentech; Gideon; MDS Nordion; Philips Medical; RSNA
Riccardo Lencioni
Honoraria - Bayer
Jorge A. Marrero
Honoraria - Bayer; Onyx
Research Funding - Bayer
Alan Paul Venook
Consultant or Advisory Role - Abbott Laboratories (U); Bristol-Myers Squibb (U); Chugai Pharma (U)
Research Funding - Bayer; Onyx
Sheng-Long Ye
No relevant relationships to disclose
Keiko Nakajima
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Frank Cihon
Employment or Leadership Position - Bayer
Masatoshi Kudo
No relevant relationships to disclose